Surrogate biomarkers are critical in cancer research and treatment because they enable faster and more efficient clinical trials. By providing early evidence of treatment efficacy, they can help in speeding up the drug approval process. Additionally, these biomarkers can assist clinicians in making more informed decisions regarding patient management, thus optimizing personalized medicine.
